Luye Pharma Sustainability Profile
Luye Pharma Group Ltd., commonly referred to as Luye Pharma, is a prominent biopharmaceutical company headquartered in China (CN). Established in 1997, the company has made significant strides in the pharmaceutical industry, focusing on innovative drug development and manufacturing. With a strong presence in major operational regions including Asia, Europe, and North America, Luye Pharma is dedicated to addressing unmet medical needs across various therapeutic areas. The company’s core products encompass a range of advanced formulations, particularly in oncology, central nervous system disorders, and cardiovascular diseases. Luye Pharma is recognised for its unique drug delivery systems, which enhance the efficacy and patient compliance of its therapies. With a commitment to research and development, Luye Pharma has achieved notable milestones, positioning itself as a key player in the global biopharmaceutical market.
DitchCarbon Score
How does Luye Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Luye Pharma's score of 38 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Luye Pharma's reported carbon emissions
In 2024, Luye Pharma reported total carbon emissions of approximately 67.6 million kg CO2e. This figure includes Scope 1 emissions of about 9.97 million kg CO2e and Scope 2 emissions of approximately 57.6 million kg CO2e. The company has shown a reduction in emissions from the previous year, where total emissions in 2023 were about 76.2 million kg CO2e, indicating a decrease of approximately 8.6 million kg CO2e. Luye Pharma's emissions data is not cascaded from any parent organization, and they have not set specific reduction targets under the Science Based Targets initiative (SBTi) or other climate pledges. The absence of Scope 3 emissions data suggests a focus on direct and indirect emissions from their operations and energy use. Overall, Luye Pharma is actively monitoring its carbon footprint, with a commitment to reducing emissions, although specific reduction initiatives or targets have not been disclosed.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 9,105,040 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 42,156,830 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
How Carbon Intensive is Luye Pharma's Industry?
How Carbon Intensive is Luye Pharma's Location?
Luye Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Luye Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.